DE60333608D1 - Biomarker zur Diagnose von Alzheimer - Google Patents

Biomarker zur Diagnose von Alzheimer

Info

Publication number
DE60333608D1
DE60333608D1 DE60333608T DE60333608T DE60333608D1 DE 60333608 D1 DE60333608 D1 DE 60333608D1 DE 60333608 T DE60333608 T DE 60333608T DE 60333608 T DE60333608 T DE 60333608T DE 60333608 D1 DE60333608 D1 DE 60333608D1
Authority
DE
Germany
Prior art keywords
alzheimer
human
patients
disease
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333608T
Other languages
English (en)
Inventor
Oezkan A Dr Yalkinoglu
Gerhard Dr Koenig
Denis Francois Prof Dr Hochstrasser
Jean-Charles Dr Sanchez
Odile Dr Carrette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02018283A external-priority patent/EP1394549A1/de
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Application granted granted Critical
Publication of DE60333608D1 publication Critical patent/DE60333608D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60333608T 2002-08-23 2003-08-11 Biomarker zur Diagnose von Alzheimer Expired - Lifetime DE60333608D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018283A EP1394549A1 (de) 2002-08-23 2002-08-23 Biomarker zur Diagnose von Alzheimer Erkrankung
EP02026643 2002-11-29

Publications (1)

Publication Number Publication Date
DE60333608D1 true DE60333608D1 (de) 2010-09-09

Family

ID=31947886

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60322719T Expired - Lifetime DE60322719D1 (de) 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer
DE60333608T Expired - Lifetime DE60333608D1 (de) 2002-08-23 2003-08-11 Biomarker zur Diagnose von Alzheimer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60322719T Expired - Lifetime DE60322719D1 (de) 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer

Country Status (10)

Country Link
EP (3) EP1953556B1 (de)
JP (1) JP4405919B2 (de)
AT (2) ATE403875T1 (de)
AU (3) AU2003251702B2 (de)
CA (6) CA2745731C (de)
DE (2) DE60322719D1 (de)
DK (3) DK2221620T3 (de)
ES (3) ES2347924T3 (de)
PT (1) PT1535076E (de)
WO (1) WO2004019043A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469312A1 (de) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnose der Alzheimer Krankheit
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
EP1694816B1 (de) * 2003-11-07 2013-08-28 Ciphergen Biosystems, Inc. Biomarker für morbus alzheimer
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
AU2006231597B2 (en) * 2005-04-06 2011-11-17 Mosaiques Diagnostics And Therapeutics Ag Polypeptide marker for diagnosing Alzheimer's disease
WO2006138325A2 (en) * 2005-06-16 2006-12-28 Vermillion, Inc. Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
EP1922325B1 (de) 2006-02-28 2011-11-30 Phenomenome Discoveries Inc. Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
EP2469279A1 (de) * 2006-03-11 2012-06-27 The Board Of Trustees Of The Leland Stanford Junior University Cystatin C, Lysozyme und Beta-2 Mikroglobulin als Biomarker für periphere Arterienerkrankung
GB0616230D0 (en) * 2006-08-16 2006-09-27 Univ Cambridge Tech Biomarkers and uses thereof
SG173418A1 (en) 2007-02-08 2011-08-29 Phenomenome Discoveries Inc Methods for the treatment of senile dementia of the alzheimer's type
EP2279420B1 (de) 2008-03-21 2014-01-29 Manuela G. Neuman VERFAHREN ZUR DIFFERENTIELLEN DIAGNOSE VON MORBUS ALZHEIMER GEGEN FRONTOTEMPORALE DEMENZ MIT FAS-L, TNF-alpha UND ccCK-18 ALS BIOMARKER
AU2009295357A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EP3079708A4 (de) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Verfahren und zusammensetzungen zur behandlung von altersassoziierten leiden
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
CN113855804A (zh) 2015-06-15 2021-12-31 小利兰·斯坦福大学托管委员会 用于治疗衰老相关病症的方法和组合物
KR102572009B1 (ko) * 2020-10-21 2023-08-29 순천향대학교 산학협력단 시스타틴 c를 포함하는 퇴행성 신경 질환 진단용 바이오마커 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
JP2002531063A (ja) * 1998-10-23 2002-09-24 ローゲル ニッシェ アルツハイマー症の診断又は予後の方法
WO2001062787A1 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of bipolar affective disorder
AU2001240909A1 (en) * 2000-03-20 2001-10-03 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001249835A1 (en) * 2000-04-03 2001-10-15 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
EP1373905A2 (de) * 2001-04-06 2004-01-02 BioVisioN AG Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
WO2003028543A2 (en) * 2001-10-03 2003-04-10 Pfizer Products Inc. Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease

Also Published As

Publication number Publication date
EP1535076B1 (de) 2008-08-06
ES2436318T3 (es) 2013-12-30
CA2746000A1 (en) 2004-03-04
CA2745724C (en) 2015-06-02
AU2003251702B2 (en) 2010-06-03
CA2745998A1 (en) 2004-03-04
CA2745569A1 (en) 2004-03-04
EP2221620A3 (de) 2010-11-24
ES2311751T3 (es) 2009-02-16
ATE475888T1 (de) 2010-08-15
EP1535076A2 (de) 2005-06-01
JP4405919B2 (ja) 2010-01-27
AU2010212316B2 (en) 2012-05-24
DK1953556T3 (da) 2010-10-25
DK1535076T3 (da) 2008-11-24
CA2746000C (en) 2014-10-21
AU2003251702A1 (en) 2004-03-11
EP1953556A3 (de) 2008-11-26
AU2010212317B2 (en) 2013-01-10
ES2347924T3 (es) 2010-11-25
JP2005536729A (ja) 2005-12-02
AU2010212317A1 (en) 2010-09-09
EP2221620B1 (de) 2013-10-02
CA2745731C (en) 2015-05-12
CA2745731A1 (en) 2004-03-04
EP2221620A2 (de) 2010-08-25
WO2004019043A2 (en) 2004-03-04
WO2004019043A3 (en) 2004-06-24
CA2745569C (en) 2015-07-14
ATE403875T1 (de) 2008-08-15
DE60322719D1 (de) 2008-09-18
DK2221620T3 (da) 2014-01-06
CA2496321A1 (en) 2004-03-04
CA2496321C (en) 2013-05-21
PT1535076E (pt) 2008-11-03
EP1953556A2 (de) 2008-08-06
EP1953556B1 (de) 2010-07-28
AU2010212316A1 (en) 2010-09-09
CA2745998C (en) 2013-11-26
CA2745724A1 (en) 2004-03-04
CA2496321E (en) 2004-03-04

Similar Documents

Publication Publication Date Title
ATE475888T1 (de) Biomarker zur diagnose von alzheimer
ATE283485T1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
HK1159249A1 (en) Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques
WO2003070894A3 (en) A non-invasive diagnostic test utilizing histone modification markers
NO20050186D0 (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
ATE474227T1 (de) Bestimmung von felinem und caninem probnp
DE602004011931D1 (de) Gleichenden diagnose von alzheimer
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
DE602004028513D1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
WO2002088303A3 (en) Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
JP4452715B2 (ja) 特定のペプチドを自閉症の指標として利用する方法
WO2007062363A3 (en) Method for diagnosing a person having sjogren's syndrome
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
BR0007702A (pt) Método e kit de diagnóstico para diagnose de endometriose
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
ATE352037T1 (de) Immunochromatographiesystem und verfahren zur gleichzeitigen identifikation von aga-und t-tg- antikörpern und verwendung dafür zur diagnose der zöliakiekrankheit
CN106661608A (zh) 十二指肠液试样作为来自胰液的成分检测用试样的适性评价方法
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
DE60334200D1 (de) Verfahren zur messung von neprilysinaktivität
AU2003299389A8 (en) PRP detection method using an aminoglycoside antibiotic
ATE489634T1 (de) In vitro methode zur klinischen diagnose.